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ABSTRACT
The main objectives of the present study were to investigate the clinical and laboratory features of 
meningococcal disease in the city of Rio de Janeiro, Brazil, during the overlap of 2 epidemics in the 
1990s. We conducted a study of a series of cases of meningococcal disease admitted in a Meningitis 
Reference Hospital. All clinical isolates available were analyzed by means of microbiological epide-
miological markers. In 1990, Neisseria meningitidis serogroup B:4,7:P1.19,15, 1.7,1 sulfadiazine-re-
sistant of the ET-5 complex emerged causing epidemic disease. Despite mass vaccination campaign 
(VaMengoc B+C®), the ET-5 clone remained hyperendemic after the epidemic peaked. In 1993 to 
1995, an epidemic of serogroup C belonged to the cluster A4 overlapped, with a signifi cant shift in 
the age distribution toward older age groups and an increase of sepsis. Serogroup C epidemics are 
a recurrent problem in Rio de Janeiro, which can be hindered with the introduction of a conjugate 
vaccine. We hope the data presented here brings useful information to discuss vaccines strategies and 
early management of suspected cases.
Keywords: Neisseria meningitidis, meningococcal disease, epidemic, meningitis, sepsis.
[Braz J Infect Dis 2010;14(3):242-251]©Elsevier Editora Ltda.
INTRODUCTION
The Rio de Janeiro state, Southeast of Brazil, 
had a total population in 2000 of 14,391,282 
inhabitants, with 5,857,904 people living in the 
city of Rio de Janeiro, the Capital of the state. 
The fi rst confi rmed epidemic due to serogroup 
C disease was registered in the beginning of 
the 1970s, when a mass vaccination campaign 
against N. meningitidis serogroup A and C was 
implemented in 1975.1 The epidemic strain was 
characterized as phenotype 2a:P1.5, 1.2 geneti-
cally related to the ET-37 complex.2 In the 1980s, 
1408 cases of meningococcal disease were re-
ported, with incidence of 1-5 cases/\100,000/\
year (Rio de Janeiro City Health Department). 
Since 1985, a steady increase of serogroup B 
clinical isolates was observed, initially attrib-
uted to an improvement in the laboratory di-
agnostic procedures in identifying meningeal 
pathogens (Figure 1). Another increase of se-
rogroup C disease was observed in 1988 and it 
peaked in the next year (Figure 1), mainly due 
to sero-subtype 2a:P1.2, which motivated the 
use of polysaccharide specifi c vaccine in some 
parts of the Rio de Janeiro state. 
From 1990 to 1999, the Rio de Janeiro City 
Department of Health received the notifi cation 
of 4147 cases of meningococcal disease (rates 
5-10/\100,000/\year), which represent about 
50% of all reported cases in the state of Rio 
de Janeiro. In 1990, the incidence rate reached 
7.3/\100,000 in the city of Rio de Janeiro, with 
isolates of N. meningitidis serogroup B (91%) 
predominating in cases diagnosed (Figures 
1, 2). These group B organisms express a class 
3 outer membrane protein, many times char-
acterized as serotype 4 (82%) and with a class 
1 protein characterized as P1.15 (45%); 55% 
were B:4:nt. A mass vaccination campaign us-
ing the VaMengoc B+C® (Finlay Institute) was 
conducted in Rio de Janeiro in the target popu-
lation aged 6-months to 9-years.3 This vaccine 
is composed of 65-95 kD high molecular weight 
subcapsular proteins and serotype-specifi c 
protein phospholipids from a Cuban B:4:P1.15 
strain added to serogroup C polysaccharide, 
and combined with aluminum hydroxide. The 
impact of this intervention in the incidence 
rates was not signifi cant and the disease level 
did not return to that found before the rise of 
serogroup B:4 organisms (Figure 2). In 1993, 
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N. meningitidis serogroup C gave rise to a new increase in 
meningococcal disease cases and in the next year an epi-
demic took place. A campaign with the vaccine VaMen-
goc B+C® was extended to all children up to 13-years old 
(Figures 1, 2). The intervention did not take into account 
a shift in the age-distribution of the disease and it did not 
halt an epidemic of meningococcal disease due to sero-
group C. In 1995, the epidemic peaked, with a recorded 
incidence of > 10/\100,000 (Figure 2), which motivated a 
second vaccination campaign to individuals aged 14 to 30-
years with a serogroup C polysaccharide vaccine. During 
that year, N. meningitidis serogroup C represented 57% of 
all patients’ isolates, with a class 2 protein normally char-
acterized as serotype 2b (65%) or 2a (21%); of the C:2b 
strains, 93% were C:2b:nt.
The Infectious Diseases State Institute São Sebastião is 
a meningitis reference hospital, located in the city of Rio de 
Janeiro, strategically built close to the harbor basin in 1889 
to receive patients with yellow fever, then epidemic in the 
city. In the 1990s, its Epidemiological Surveillance Unit de-
tected two epidemic waves of disease caused fi rst by sero-
group B followed a few years later by serogroup C N. menin-
gitidis. We have studied the clinical and laboratory features 
of meningococcal disease based on the records of the State 
Reference Hospital, between 1990 and 1996, to describe the 
clinical manifestations and the characterization of N. men-
ingitidis clinical isolates using different microbiological epi-
demiological markers.
 
MATERIAL AND METHODS
Setting, study population, and study design 
A retrospective descriptive study was conducted in a series 
of cases of meningococcal disease admitted between 1990 
and 1996 in the Meningitis Reference Hospital, with resi-
dence in the city of Rio de Janeiro. During the study period, 
the Reference Hospital had admitted 77% (2413/3150) of all 
reported cases in that city. Also, its laboratory of bacteriol-
ogy has identifi ed the species and characterized the capsu-
lar serogroup of more than 90% (1284/1426) of all known 
N. meningitidis clinical isolates in the Rio de Janeiro region 
(Rio de Janeiro City Department of Health). We divided 
the study in three defi ned periods: 1990 to 1992 (epidemic 
serogroup B disease), 1993 to 1995 (epidemic serogroup C 
disease), and 1996 (post-vaccination campaign).
Case deﬁ nition and data collection
Meningococcal disease patients were defi ned as confi rmed 
cases – culture (heated blood agar) or antigen detection 
(latex agglutination kit, bioMérieux®) or direct smear 
(Gram stain) – or probable cases – a clinical picture with 
fever of abrupt onset and suggestive hemorrhagic skin le-
sions – whenever conventional bacteriological methods 
were negative or unavailable. Latex agglutination test were 
only available from 1993 onwards. A census of patients with 
meningococcal disease was carried out based on diagnosis 
at admission and discharge. Medical charts and laboratory 
records of cases enrolled were carefully reviewed.
Collection, characterization and typing of clinical 
isolates of N. meningitidis
All viable N. meningitidis isolated from CSF or blood from 
meningococcal disease patients (meningitis and/or sepsis) 
between 1990 and 1996 were analyzed in a single block of 
time by means of microbiological epidemiological markers. 
The growth of one oxidase-positive colony, with the appear-
ance of Gram-negative diplococci was identifi ed by a nega-
tive β-galactosidase test and the ability to oxidize glucose 
and maltose but not lactose and sucrose in cystine tryptic 
agar. The serogroup of N. meningitidis was determined by 
means of slide agglutination with specifi c antiserum groups 
A, B, C, W
135
, Y, 29E, X, and Z. Non-groupable strains were 
genetically related to groupable isolates found in the pop-
ulation using genogrouping polymerase chain reaction 
(PCR) assays as previously reported.4 Sero-subtyping has 
been performed using whole-cell bacterial suspension and 
monoclonal antibodies in the National Meningitis Refer-
Figure 2: Annual incidence rates of meningococcal disease 
and indications of mass immunizations campaigns in the city 
of Rio de Janeiro, 1974-2008. 
Figure 1: Annual distribution of Neisseria meningitidis 
capsular serogroups causing invasive disease in the city of 
Rio de Janeiro, 1975-2008.
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ence Centre, Adolfo Lutz Institute, São Paulo. Minimum in-
hibitory concentration (MIC) of penicillin (relative resistant 
0.12-0.25 µg/mL; resistant ≥ 0.5 µg/mL), rifampicin (relative 
resistant 1 µg/mL; resistant ≥ 2 µg/mL), and sulfadiazine (re-
sistant ≥ 8 µg/mL) were determined by means of E-test 
strips (AB BIODISK®) on Müller-Hinton agar (OXOID® 
CM0337) supplemented with 5% sheep blood following 
the manufacture’s instruction. Culture plates were incu-
bated at 35˚ C in a candle jar for 24 hours before reading.
Multilocus enzyme electrophoresis (MLEE) was 
performed and analyzed as described by Selander et al. 
(1986).5 The overall genetic relatedness of N. meningi-
tidis was examined by an analysis of electrophoretically 
demonstrable allelic variation at 13 structural genes en-
coding enzymes in 56 serogroup B, 175 serogroup C, and 
2 serogroup W
135
 isolates, recovered from meningococ-
cal disease patients between 1990 and 1995. The electro-
phoretic types (ETs) were determined by analysis of al-
lelic variations in 13 enzymes assayed, and each unique 
set of alleles was defined as a multilocus enzyme genotype 
(ET). Allele profile of each clinical isolate was compared 
with those previously described; however ET numbers 
were not cognate with those previously assigned.
Data analysis 
We have summarized the clinical presentation of cases 
enrolled in three categories taking into account clini-
cal evidence of sepsis – hemorrhagic skin lesions – and 
laboratory results for biological specimens – cerebrospi-
nal fluid (CSF) white blood cell (WBC) count: meningi-
tis (absence of hemorrhagic skin lesions and CSF WBC 
count >10 per mm3), sepsis and meningitis (hemorrhagic 
skin lesions and CSF WBC count >10 per mm3) or sepsis 
(hemorrhagic skin lesions and CSF WBC count ≤10 per 
mm3 or fever and hemorrhagic skin lesions in the absence 
of diagnostic lumbar puncture). Co-primary and second-
ary cases were used to identify when household members 
became ill with meningococcal disease following onset of 
the initial case before or after 24 hours in their household, 
respectively. Patients were stratified into the following 
age categories: < 1 y, 1-4 y, 5-9 y, 10-14 y, 15-19 y, 20-49 
y, ≥ 50 y. Clinical picture has been defined as prodromus 
– sore throat, otalgia, and fits (sneezing, cough or nasal 
drainage ) – and signs and symptoms recorded at presen-
tation – fever, neck stiffness, headache, vomits, petechial 
rash, extensive ecchymoses, conjunctivitis, abdominal 
pain, diarrhea, arthritis, convulsion, systemic shock, lo-
calized neurologic signs. Time between onset of disease 
and hospital admission, time of hospitalization, and out-
come (discharge, death or transference) were categorized 
in hours. Information of pre-admission antibiotic treat-
ment was collected. Also, we have used the outcome data 
that were available at hospital discharge.
Statistical analysis 
Clinical and epidemiological data were analyzed using Epi 
InfoTM (Version 3.3.2, CDC). The heterogeneity of propor-
tions between groups was compared using the chi-squared 
test with Yates’s correction or by Fisher’s exact test for statis-
tical signifi cance. All results for continuous variables are ex-
pressed by means. Exact binomial 95% confi dence intervals 
(CI) are reported.
Data generated by MLEE were analyzed as proposed in 
the report of Selander et al. 1986.5 Brieﬂ y, an index of ge-
netic relatedness was determined by weighing the degree 
of diversity at each of the 13 enzyme loci (electromorphic 
profi le), and similarities among the ETs were assessed by 
phylogenetic analysis. Genetic diversity (h) at an enzyme lo-
cus among either ETs or isolates was calculated from allele 
frequencies (h). Mean genetic diversity is the arithmetic av-
erage of h values over all loci. Genetic distance (d) between 
pairs of ETs was expressed as the proportion of enzyme loci 
at which dissimilar alleles occurred (mismatches). A distinc-
tive cluster of ETs, designated as ET-complex, is composed 
by a group with identical allele profi le or ETs with the occur-
rence of dissimilar alleles at 1 - 2 (d of 0.08 to 0.15) of the 13 
loci. Numerical analysis of MLEE data based on 13 enzyme 
loci was performed using the NTSYS-pc version software 
package (Rolf FJ, Exeter Software®) and affi nities among 
strains were calculated using the Dice coeffi cient. The simi-
larity matrix was transformed into a dendogram by means 
of unweighed pair group method with arithmetic averages 
(UPGMA) algorithm.7
 
RESULTS
From 1990 to 1996, we have found through the hospital 
and laboratory records 2413 diagnosed cases of meningo-
coccal disease. After review, we excluded 75 cases because 
their diagnoses did not meet the criteria for inclusion. Of 
the remaining 2338 (90-92 = 908; 93-95 = 1059; 96 = 371) 
patients, medical charts and laboratory records were thor-
oughly reviewed. Of these, 3% had not been notifi ed to 
the Rio de Janeiro City Department of Health. Diagnostic 
lumbar puncture was performed at presentation in 94% 
(2197/2338) of the patients enrolled. In addition to 1644 
(70%) patients confi rmed through conventional bacteriolo-
gy, we included 694 (30%) probable cases with hemorrhagic 
rash and either meningitis and/or sepsis. Of these confi rmed 
cases, 78% (1284) were detected solely by culture, 12% (194; 
93-95 = 117; 96 = 77) by antigen detection, and 10% (166) 
by direct smear. The proportion of culture-proven cases 
were 63% (567), 53% (562), and 41% (155) according with 
the three periods of the study. In all, 11% (90-92 = 11%; 93-
95 = 14%; 96 = 16%) of the patients had received at least on 
dose of antibiotics by injection before hospital admission, 
with the presence of a petechial rash in 80% of them. A few 
Meningococcal disease in Rio de Janeiro, Brazil
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patients (1%; 25/2338) had history of recurrent meningo-
coccal disease, with 2 or 3 previous episodes. Of the total, 3% 
of the patients (75/2338) referred to a case of meningococ-
cal disease previously diagnosed in their household, which 
could be defi ned as co-primary (n = 38) or secondary cases 
(n = 37). The number of secondary cases was higher be-
tween 1993 and 1995 (4%; 95% CI 3-6%), compared with 
the previous period (2%; 95% CI 1-4%) (χ2 = 5; p < 0.05). 
Although meningococcal disease affected more males 
(55%) than females (45%) above 49-years of age, there was 
a preponderance of females (62%) with infection (χ2 = 6; 
p < 0.05). The relation male:female was 0.62 in patients old-
er than 49 years. The overall average age was 10-years old 
(range, 23 days to 72 years) and the median was 6-years old. 
The average age of serogroup B meningococcal disease pa-
tients was 11-years old (median = 6-years) and for patients 
from whom N. meningitidis serogroup C was recovered the 
average was 12-years old (median = 9-years). For those con-
fi rmed cases, 35% (90-92 = 33%; 93-95 = 37%) and 49% 
(90-92 = 47%; 93-95 = 49%) were in the age category 10 to 
29-years (χ2 = 19; p < 0.01), respectively. There was a change 
in the age distribution toward older age groups in the sero-
group C epidemic years, with a signifi cant increase in the 
number of cases in teenagers 15 to 19-years old (90-92 = 6%; 
93-95 = 12%; χ2 = 18.7, p < 0.01). The seasonal pattern of 
infection for these serogroups had discrete distinction, the 
highest number of infections being in the winter season for 
serogroup B and in the spring for serogroup C.
The prodromus registered at presentation were fi ts (8%), 
sore throat (4%), and otalgia (2%). Fits were more prevalent 
in infants (13%) and adults 20 to 49-years (12%). Sore throat 
was a more frequent complaint in teenagers 15 to 19-years 
(9%). The clinical signs and symptoms of confi rmed and sus-
pected cases of meningococcal disease and specifi c features 
of the disease according to the age of patients at presenta-
tion are presented in Table 1. Some clinical features asso-
ciated with a worse prognosis, i.e., extensive ecchymoses, 
diarrhea, absence of neck stiffness, and shock were more 
frequent among suspected cases (p < 0.05). There were not 
major differences in the clinical pattern of serogroup B and 
C disease. A suggestive rash was associated with 55% of 
serogroup B disease, whilst it was associated with 57% of 
serogroup C disease (p > 0.05). However, the presence of a 
petechial rash had a signifi cant variation between the fi rst 
(65%; 95%CI 61%-68%) and second (73%; 95%CI 70%-
76%) period of this study (χ2 = 14; p < 0.01). This trend 
was also noticed among confi rmed (90-92 = 50%; 93-95 = 
60%; χ2 = 12; p < 0.01) and suspected cases (90-92 = 89%; 
93-95 = 94%; χ2 = 3.7; p = 0.05). Purpura was markedly 
increased in children (5-9 years: 72% x 84%), teenagers (15 
to 19-years: 56% x 72%), and adults (20-49 years: 56% x 
70%) after 1992 (p < 0.05). 
Patients were classifi ed as meningitis (30%), sepsis and 
meningitis (58%), and sepsis (12%). The percentage of pa-
tients confi rmed through microbiological techniques accord-
ing to the clinical manifestation was 90%, 56%, and 16%, re-
spectively. The proportion of patients presenting with sepsis 
was 8% (95%CI 6% - 10%) between 1990 and 1992, which 
turned to be 15% (95%CI 13%-17%) during the serogroup 
C epidemic years (χ2 = 21; p < 0.01). Although the rise of 
patients classifi ed as sepsis was observed in all age catego-
ries, it only reached statistical signifi cance in children 5 to 
9-years and adults 20 to 49-years (p < 0.01). The number 
of patients with sepsis had a statistically signifi cant increase 
both in culture-proven (90-92: 2%; 93-95: = 7%; 96: = 10%) 
and suspected cases (90-92: 18%; 93-95: 31%; 96: 39%).
Table 1. Proportions (%) of signs and symptoms at presentation of all cases enrolled according to the 
laboratory results for biological specimens and age category of patients
Signs and symptoms  Confirmed Suspected Infants Children Teenagers Adults Elderly
             (%) cases cases (< 1 year) (1-9 year) (10-19 year) (20-49 year) (> 49 year)
Fever 95 95 97 96 92 92 96
Headache 56 48 n/a 48 86 82 86
Petechiae 54 89 45 75 68 56 54
Extensive ecchymoses 21 41 18 34 27 22 18
Neck stiffness 86 67 59 77 87 89 90
Convulsion 6 8 7 8 5 5 14
Arthritis 10 13 9 12 8 14 21
Diarrhoea 3 6 9 4 3 4 18
Impaired consciousness 47 42 31 45 46 57 68
Vomitus 79 70 67 76 82 71 71
Abdominal pain 3 4 n/a 4 4 0 4
Localized neurologic signs 3 2 5 2 3 7 4
Systemic shock 7 24 14 15 12 11 11
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Outcome and time of hospitalization according to age 
category, sex, and clinical manifestation are summarized 
in Table 2. Almost all patients either received ampicillin 
(59%) or penicillin (40%) for a mean time of 7 to 10 days. 
The patients have reached the hospital within a mean time 
of 48 hours (range, 1 hour to 15 days) of the start of their 
illness. This interval was ≤ 24 hours for 59% of the pa-
tients at presentation (≤ 12 h = 13%; 13-24 h = 46%), 25-
48 hours for 18%, 3-7 days for 21%, and > 7 days for 2%. 
Of the patients who survived, 85% had ≥ 24 hours history 
of their illness. Ninety two percent of the deaths occurred 
in the fi rst 2 days after the start of the treatment; 70% oc-
curred during the fi rst 12 hours (23% at presentation; 25% 
fi rst two hours; 52% 3-12 hours). The case-fatality rates 
for sepsis decreased during the study period (90-92 = 45%; 
93-95 = 28%; 96 = 30%).
About 90% of the patients with a fatal outcome had 
vasculitic skin lesions; 39% were confi rmed cases and 61% 
were probable cases (χ2 = 7; p < 0.01). Patients with purpura 
(20%) or extensive ecchymoses (63%) had a higher chance 
to evolve with systemic shock compared with those without 
a suggestive rash (2%) (p < 0.01). Serogroup C disease had 
a slight higher chance to be associated with a fatal outcome 
(8%) than serogroup B disease (6%) (p > 0.05). Neverthe-
less, this is diffi cult to be correctly estimated because only 
43% of the deaths were confi rmed cases; besides, confi rmed 
cases had a lower chance to die (7%; 90-92 = 5%; 93-95 = 
7%; 96 = 6%) compared with probable cases (17%, 90-92 = 
17%; 93-95 = 13%; 96 = 14%) (χ2 = 40; p < 0.01).
In 1990 to 1992, serogroup B predominated in cases di-
agnosed (89%). Serotype 4 was associated with 79% of sero-
group B clinical isolates; 47% were B:4:P1.15 and 52% were 
B:4:nt. 
In 1993, the introduction of the P1.7 monoclonal an-
tibody in the sero-subtyping panel disclosed that 35% of 
the B:4 (80%) strains expressed this subtype; 49% were 
B:4:P1.15. It is necessary to point out the concomitant de-
cline of the B:4:nt isolates to 16% (93 = 31%; 94 = 4%; 95 
= 14%; 96 = 4%). Subsequently they were characterized as 
B:4,7:P1.19,15 and B:4,7:P1.7,1. Serogroup C represented 
9% of all clinical isolates within the fi rst period. Serotype 
2a was usually associated with subtype P1.2 and serotype 
2b with subtype P1.3; 46% were C:NT:nt. In 1993 to 1996, 
43% of the confi rmed cases were due to capsular serogroup 
C. At that time, 54% of N. meningitidis serogroup C pa-
tients’ isolates expressed a class 2 protein characterized as 
2b and 26% as 2a; 16% were C:NT:nt. Of the C:2b isolates, 
82% (93 = 29%; 94 = 62%; 95 = 93%; 96 = 96%) were 
nonsubtypable (nt). It was shown that most of C:2b iso-
lates express the subtype P1.10, which was found in 94% 
(94 = 95%; 95 = 93%; 96 = 92%) of tested strains. Four 
serogroup C organisms express a class 3 outer membrane 
protein, characterized as sero-subtype 4:P1.15, P1.7, nt. 
Only one N. meningitidis recovered was designated as non-
Table 2. Outcome and time of hospitalization according to age, sex, and clinical manifestation 
of all cases enrolled
     Patients (%) per days of hospitalization                                Case-fatality rates (%)
Age group   10 11 a 15 > 15 Overall Male Female 
(years)  
< 1 27 32 41 15 18 13
1 - 4 67 25 8 10 10 9
5 - 9 76 19 5 12 10 13
10 - 14 87 10 3 5 4 5
15 - 19 82 16 2 5 3 8
20 - 49  73 17 10 6 5 7
 50  57 25 18 22 19 22
Total 71 20 9 10 9 10 
Meningitis 63 24 13 2 3 3
Septicaemia + Meningitis 73 19 8 9 8 9
Septicaemia 88 9 3 33 32 35
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groupable (NG:2a:P1.2), which was later genetically related 
to the serogroup W
135
 by means of PCR.
On a nonselective basis, 13% of the N. meningitidis sero-
group B stratifi ed by sero-subtype were randomly selected 
and analysed by MLEE. In the collection of serogroup B iso-
lates, 4 of the 13 enzyme loci were monomorphic and 9 were 
polymorphic for two to four alleles. The average number of 
alleles per locus was 1.9. A total of 9 distinctive multilocus 
enzyme genotypes were identifi ed, for which mean genetic 
diversity per locus was 0.33. There was less genetic diversity 
per locus among isolates (h = 0.15), a result of the connected 
fact that one ET was represented by multiple isolates. The 
majority (68%) of serogroup B (B:4:P1.15 = 53%; B:4:P1.7 
= 24%; B:4:nt = 18%; B:2a:P1.2 = 5%) organisms present-
ed a unique set of alleles defi ned as ET-2 (B:4,7:P1.19,15; 
N44/89) of the distinctive cluster of ETs, designated as the 
ET-5 complex (Figure 3). Also, 16% were represented by four 
clones genetically related to this complex diverging from the 
ET-2 at a genetic distance of 0.08 - 0.15. The other serogroup 
B isolates (16%) were assigned to four ETs not related to the 
ET-5 complex (d = 0.31 - 0.46). The ET-1 (B:15:P1.7,16; 
H44/76) of the ET-5 complex was represented by four 
N. meningitidis C:4 isolates. All the organisms within 
the ET-5 complex showed resistance to sulphonamide 
(MIC ≥ 8 µg/mL) at an average MIC of 146 µg/mL (range, 
8 - 256 µg/mL); one isolate was relatively resistant to penicil-
lin (MIC of 0.125 µg/mL).
All serogroup C patients’ isolates sero-subtyped available 
(80%) were selected to determine multilocus enzyme geno-
types. In the collection of serogroup C isolates, 9 of the 13 en-
zyme loci were polymorphic for two to three alleles. The aver-
age number of alleles per locus was 1.9. A total of 19 distinctive 
multilocus enzyme genotypes were identifi ed, for which mean 
genetic diversity per locus was 0.27. There was less genetic di-
versity per locus among isolates (h = 0.07), reﬂ ecting the cir-
cumstance that one unique ET was represented by the majority 
of the isolates (n = 142). The ET-40 (C:2b:P1.3; N1002/90) was 
represented by 81% of the serogroup C organisms (C:2a:P1.2 
= 25%; C:2a:P1.3 = 1%; C:2a:nt = 11%; C:2b:P1.10 = 58%; 
C:2b:nt = 5%), which belongs to a cluster of ETs, designated 
as the cluster A4 (Figure 3). There were 14% assigned to eleven 
ETs related to this cluster, which diverged from the ET-40 at d 
of 0.08 - 0.15. Only 5% of the serogroup C isolates were identi-
fi ed to multilocus genotypes unrelated to anything else in the 
database, which diverged from the ET-40 at d of 0.23 - 0.38. 
One N. meningitidis serogroup W
135
:19:nt isolate genetically be-
longed to the cluster A4, with an allele profi le closely related to 
the ET-40 (d of 0.08). Of the organisms within the cluster A4, 
36% were sulfadiazine-resistant (MIC ≥ 8 µg/mL) and one was 
relative resistant to penicillin (MIC of 0.125 µg/mL).
Figure 3: Genetic relationships of multilocus enzyme genotypes of Neisseria meningitidis strains. 
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DISCUSSION
Meningococcal disease is a major infectious fever emer-
gency, which remains a signifi cant cause of death in young 
children.8 The epidemics caused by serogroup B of the ET-5 
complex have affected mainly children below 5-years of age 
with a peak of incidence in adolescents.3,9-12 Alternatively, in 
Great Britain phenotypes associated with the ET-5 complex 
caused a much smaller proportion of infections in children 
< 4-years of age than in patients > 5-years of age.13 Although 
meningococcal disease affects mainly children during epi-
demics the proportion of patients aged greater than 4-years 
increase signifi cantly.14-17 Serogroup C disease and the me-
dian age of cases have steadily risen in Europe and North 
America during the last decade.18-25 
The distribution of cases of meningococcal disease by 
sex showed a predominance of males, but when they were 
stratifi ed by age group there was a predominance of female 
older than 49-years. Nevertheless, in Europe there was also 
a preponderance of females with infection (M:F = 0.94) at 
15 to 17-years of age.13,26 Although a statistically signifi cant 
inﬂ uence of sex (female) in the chance to die was demon-
strated in a previous investigation,27 this could not be sup-
ported elsewhere.28-30
In the 1990s, an increase of patients presenting with 
sepsis alone has been associated with the emergence of se-
rogroup C invasive infection, especially in children18,20 and 
adolescents.30 In fact, some studies have pointed out sero-
group C disease with a worse outcome.21,25,30,31 Despite of 
that, several reports have shown that case-fatality rates have 
fallen in recent years despite the observation that sepsis alone 
has arisen.20,22,32,33 This is the result of several factors, high-
lighting immediate administration of antibiotic therapy,33 
the recognition and treatment of patients who may have 
complications,34 the establishment of specialized mobile 
intensive care teams,35 centralization of care of seriously ill 
patients in an intensive care unit (ICU),32 and dissemination 
of guidance about early recognition and management.36,37
Clinical presentation of meningococcal disease in 2338 
patients studied in the city of Rio de Janeiro demonstrated 
the importance of hemorrhagic rash, a clinical manifesta-
tion of sepsis and the fi rst classic symptom of meningococ-
cal disease to spring. The serogroup C epidemic in Rio de 
Janeiro was accompanied both by an excess of patients with 
a suggestive rash and an increase of cases diagnosed as sepsis 
alone, an indication of the spread of a hipervirulent strain 
when the “force of infection” was high. Despite the increase 
in sepsis the overall case-fatality rate remained stable, and 
for patients with sepsis decreased. A possible bias of investi-
gations of meningococcal disease conducted in a Reference 
Centre is the exclusion of the most severe cases, which might 
have not had the chance to reach it. An excess of deaths at 
presentation (23%) and following hospital admission (25%) 
is an indicative that the most severe cases did reach the Ref-
erence Hospital. Unfortunately, many of those patients who 
died reached the Hospital without prior antibiotic therapy 
and safe interhospital transfer. 
Initial unspecifi c symptoms and clinical presentation 
differed according to the age of patients. Infants were more 
likely to develop meningitis in the absence of neck stiffness 
and petechiae, preceded by an antecedent of upper respira-
tory infection. Diarrhea, an unspecifi c sign possible associ-
ated with diagnostic delay and death,38 was frequent in the 
very young and the very old. It is sometimes an early feature 
of the condition,39 and it can be severe enough to suggest a 
diagnosis of acute gastroenteritis.16 Patients above 49-years 
of age were distinguished by a clinical picture of meningitis 
without a rash, neck stiffness, impaired consciousness, and 
convulsions. Both groups had a presentation and anteced-
ents which might have led to diagnostic delays and prob-
lems in the initial case management; thus, it may explain in 
part the highest case-fatality rates. They also necessitated a 
longer time of hospitalization (Table 2). Normally, children 
developed sepsis or meningitis with a sepsis component, ac-
companied by extensive purpura, systemic shock, and late 
hospital complications. Teenagers and adults had a higher 
chance to develop meningitis with the classic triad: fever, 
headache, and neck stiffness. In spite of that, teenagers were 
more likely to have a vasculitic rash, whereas adults had im-
paired consciousness and localized neurologic signs. 
In both epidemics periods a clonal structure could be 
defi ned by means of MLEE, a characteristic of the popu-
lation biology of this bacterium during epidemic waves 
of disease.40,41 Serogroup B epidemic disease has initially 
evolved gradually and after the epidemic peak it remained 
throughout the decade on a sustained hiperendemic level 
(Figures 1, 2). The clones of the ET-5 complex underwent 
several recombination events during the intercontinental 
spread,42 that have generated the B:4,7:P1.19,15 variant re-
sponsible to epidemic disease in the south and south-east 
of Brazil.12,43 It is important to notice, the surface antigen 
(PorA) P1.7,1 variant emerged in the Rio de Janeiro Region, 
which had not been associated with the B:4 Brazilian strains 
before.12,43 These clones were sulfadiazine-resistant, in con-
trast to serogroup and serotype, an essentially invariant prop-
erty of clones of the ET-5 complex.10,44 The recovery of C:4 
strains of the ET-5 complex (Figure 3) suggests that capsule 
switching has occurred after the mass vaccination campaigns, 
probably as the result of transformation and horizontal DNA 
exchange in vivo.45 The C:4,7:P1.19,15 strain is noteworthy to 
have recently caused a case cluster in south of Brazil.46
The epidemic of serogroup C disease rapidly evolved af-
ter 1993, presenting a similar clinical and epidemiological 
pattern found in simultaneous events elsewhere.42,47-50 The 
two striking features of the serogroup C epidemics in the 
1990s were a changing in clinical presentation, with the rise 
of sepsis, and a shift towards a higher incidence of the dis-
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ease in adolescents.18-21,25,30 A higher incidence of disease in 
adolescents has serious implications for community health, 
due to their extensive net of social contacts and the possi-
bility of acquisition of infection in work or study or social 
activity places.47,51 Clones belonging to the cluster A4 and to 
the ET-37 complex have been implicated with epidemics of 
serogroup C in the America and Europe Continents.24,25,31,49,52 
In the second half of the 1990s the cluster A4 has displaced 
the ET-37 complex in Spain and Portugal,24,52 and more re-
cently in Italy and Poland.31,53 In Rio de Janeiro, the cluster 
A4 epidemic strains often express sero-subtype 2b:P1.10 
(Figure 3), which has caused epidemic and hiperendemic 
waves of disease in other parts of Brazil but expressing an 
unusual subtype, P1.3.2,11,12
Serogroup C disease has emerged in the Rio de Janeiro 
metropolitan area once more after the year 2000, and now 
it represents more than 90% of the clinical isolates (Figure 
1). The strains have mainly been associated with the phe-
notypes C:23:P1.14-6, C:4,7:P1.19,15, P1.7.1 sulfadiazine-
resistant (SR), and, to lesser extent, C:2a:P1.5,2. At least four 
outbreaks investigated have motivated immediate action 
in the cities of Parati (2004: C:23:P1.14-6), Rio de Janeiro 
(2006: C:4,7:P1.7,1 SR), Petrópolis (2007: genogroup C), 
and Búzios (2008: C:2a:P1.5) (data not shown). The rise of 
capsular serogroup W
135
 isolated from clinical cases was also 
noticed (Figure 1).
Penicillin relative resistance (PenRR) was detected in two 
N. meningitidis belonging genetically to the ET-5 complex 
or to the cluster A4. The PenRR strains belonging to a single 
clone of the cluster A4 was found in Italy a few years ago.53 
Also, the dissemination of the hypervirulent cluster A4, 
among PenRR serogroup C isolates in Portugal has recently 
been reported.24 A reduction of the penicillin intermediate 
breakpoint to 0.094 µg/mL has been suggested when the E-
test method is used;54 however the application of this level 
of intermediate resistance would not alter our data. The in-
crease of cases of meningococcal disease caused by PenRR 
isolates has been followed by publications of only a few re-
ports of treatment failure, some of then inconclusive or just 
showing a prolonged time to abatement of fever.55-58
Accumulating clinical experience has gradually outlined 
the epidemiology of meningococcal disease, including the 
epidemic and the endemic disease, the usual clinical signs 
according to age of patients, and causative strains.59 Mass 
vaccination campaign, if appropriately implemented, has 
been documented to halt an epidemic of meningococcal 
disease.48 Although successful vaccination strategy has to 
cover all populations at risk of disease sometimes the stock 
of vaccine is not suffi cient or unavailable.60 Thus, it is neces-
sary to reinforce that proper case management is the only 
effective measures against invasive disease,37,61,62 and this can 
be the only remaining strategy during epidemics.60 In our 
context, the routine implementation of serogroup C glyco-
protein conjugate vaccine is of paramount importance, due 
to the inﬂ uence of disease burden and periodic epidemics 
of serogroup C since the 1970s. We hope the data presented 
here brings useful information to discuss vaccines strategies, 
revise the guidance to early management of suspected cases, 
and evolutionary approaches to analysis of N. meningitidis 
strains.
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